Literature DB >> 17289905

HDAC inhibitors and cardiac safety.

Rhoda Molife, Peter Fong, Michelle Scurr, Ian Judson, Stan Kaye, Johann de Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17289905     DOI： 10.1158/1078-0432.CCR-06-1715

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  19 in total

1.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

3.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.

Authors:  Denise A Yardley; Roohi R Ismail-Khan; Bohuslav Melichar; Mikhail Lichinitser; Pamela N Munster; Pamela M Klein; Scott Cruickshank; Kathy D Miller; Min J Lee; Jane B Trepel
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

4.  Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.

Authors:  Masafumi Ikeda; Izumi Ohno; Hideki Ueno; Shuichi Mitsunaga; Yusuke Hashimoto; Takuji Okusaka; Shunsuke Kondo; Mitsuhito Sasaki; Yasunari Sakamoto; Hideaki Takahashi; Rina Hara; Shingo Kobayashi; Osamu Nakamura; Chigusa Morizane
Journal:  Invest New Drugs       Date:  2018-07-11       Impact factor: 3.850

5.  A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Authors:  Douglas W Sborov; Alessandro Canella; Erinn M Hade; Xiaokui Mo; Soun Khountham; Jiang Wang; Wenjun Ni; Ming Poi; Christopher Coss; Zhongfa Liu; Mitch A Phelps; Amir Mortazavi; Leslie Andritsos; Robert A Baiocchi; Beth A Christian; Don M Benson; Joseph Flynn; Pierluigi Porcu; John C Byrd; Flavia Pichiorri; Craig C Hofmeister
Journal:  Leuk Lymphoma       Date:  2017-03-07

Review 6.  Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Swaminathan P Iyer; Francine F Foss
Journal:  Oncologist       Date:  2015-06-22

7.  Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.

Authors:  Anne M Noonan; Robin A Eisch; David J Liewehr; Tristan M Sissung; David J Venzon; Thomas P Flagg; Mark C Haigney; Seth M Steinberg; William D Figg; Richard L Piekarz; Susan E Bates
Journal:  Clin Cancer Res       Date:  2013-04-15       Impact factor: 12.531

Review 8.  Signaling effectors underlying pathologic growth and remodeling of the heart.

Authors:  Jop H van Berlo; Marjorie Maillet; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

9.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Authors:  Winnie Yeo; Hyun C Chung; Stephen L Chan; Ling Z Wang; Robert Lim; Joel Picus; Michael Boyer; Frankie K F Mo; Jane Koh; Sun Y Rha; Edwin P Hui; Hei C Jeung; Jae K Roh; Simon C H Yu; Ka F To; Qian Tao; Brigette B Ma; Anthony W H Chan; Joanna H M Tong; Charles Erlichman; Anthony T C Chan; Boon C Goh
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

10.  Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Authors:  Laleh Amiri-Kordestani; Victoria Luchenko; Cody J Peer; Kambiz Ghafourian; James Reynolds; Deb Draper; Robin Frye; Sue Woo; David Venzon; John Wright; Monica Skarulis; William D Figg; Tito Fojo; Susan E Bates; Richard L Piekarz
Journal:  Clin Cancer Res       Date:  2013-06-11       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.